Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Injected antibodies provide long-term protection against HIV

Trial results show extended protection against HIV in monkeys treated with monoclonal antibodies.

So far, little progress has been made in generating an effective vaccine against HIV. An alternative approach is the prophylactic administration of monoclonal antibodies (mAbs) against the virus, a strategy used against hepatitis A before a vaccine was available. 

Researchers explored the efficacy of four anti-HIV neutralising mAbs in 24 monkeys. After receiving the mAb infusion, the animals were challenged weekly with a low dose of a chimeric simian/HIV. 

The researchers found that mAb administration extended the median time to infection by between 8 and 13 weeks, compared with a median of 3 weeks among control animals. One treated monkey was protected for 23 weeks. 

Reporting in Nature (online, 27 April 2016)[1], the team says that the use of anti-HIV mAbs in areas where the virus is endemic could have a major impact on transmission.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201124

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • HIV-infected T-cell

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.